Trial Profile
Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2023 Primary endpoints has been amended and trial focus has been shifted to Tu and Ar.
- 01 Aug 2021 Results assessing safety and efficacy of the combination of trastuzumab and ruxolitinib in patients with trastuzumab resistant metastatic breast cancer, published in the Breast Cancer Research and Treatment.
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.